Letrozole Accord (Letrozole)

Letrozole works by reversibly inhibiting the aromatase enzyme (CYP19A1), which converts androgens into estrogens. This inhibition sharply reduces circulating estrogen, removing a key growth signal for estrogen‑dependent breast cancer cells and thereby slowing or stopping tumor progression.

The exact dose is determined by the prescribing physician based on the patient’s clinical condition. In many treatment protocols, a common starting point is 2.5 mg taken orally once daily, but the prescriber may adjust the regimen according to individual response and tolerability.

Letrozole is contraindicated during pregnancy and breastfeeding because it can interfere with estrogen production essential for fetal development and lactation. Women of child‑bearing potential should use effective contraception, and the drug should be avoided in nursing mothers.

To order Letrozole Accord, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole belongs to the third‑generation aromatase inhibitors and is often compared with anastrozole and exemestane. All three lower estrogen production, but letrozole generally achieves a slightly greater reduction in estradiol levels, which can translate into marginally improved disease‑free survival in some studies.

Letrozole tablets should be stored at ambient temperature, below 25 °C, in the original blister or bottle. Keep them away from excess moisture, direct sunlight, and heat sources. Do not use tablets that appear discoloured or damaged.

Letrozole Accord is taken orally as a whole tablet, with or without food. Patients should swallow the tablet with water and follow the dosing schedule prescribed by their healthcare professional, typically once daily at the same time each day.

Serious risks include severe liver injury, osteoporotic fractures due to reduced estrogen, and rare but life‑threatening events such as pulmonary embolism or anaphylactic reactions. Patients should be monitored regularly for signs of hepatic dysfunction, bone loss, and cardiovascular complications.

Letrozole should not be used by premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any tablet excipients. Caution is also advised for patients with severe hepatic impairment or uncontrolled osteoporosis.